Overview

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Status:
Recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma. Moreover, this study will evaluate the safety and efficacy of Darolutamide and Goserelin combination in patients with androgen receptor-positive salivary gland carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Center Hospital East

Collaborator:

Bayer Yakuhin, Ltd.

Treatments:

Goserelin